Retina Consultants of America Physicians Present Research on Clinical Studies for Diabetic Retinopathy, Age-Related Macular Degeneration at ASRS Annual 2025

[July 30] Conshohocken, Pa. – Physicians across the Retina Consultants of America (RCA) network, a leading management services organization (MSO) of retina specialists, will present research on clinical studies and advances in retinal care at the American Society of Retina Specialists (ASRS) annual meeting, which begins today in Long Beach, California.

Physicians will participate in more than 20 sessions during the four-day event, presenting case studies on investigational products and novel therapeutic approaches for a range of eye diseases and disorders, including diabetic retinopathy, age-related macular degeneration (AMD), retinal detachment and ocular oncology.

“As an organization dedicated to delivering the highest quality patient care and saving vision through innovation, we take great pride in contributing to cutting-edge clinical research aimed at improving outcomes for patients with retinal diseases,” said Charles C. Wykoff, MD, PhD, Director of Research at Retina Consultants of Texas and Chairman of Research at Retina Consultants of America. “Our engagement at this conference reflects our commitment to patients, the field of retina, groundbreaking clinical trials and big-data analyses.”

RCA — which is a part of Cencora — is a network of premier retina practices across 23 states. Each practice is independently led by the partner physicians, allowing them to retain clinical autonomy. A global leader in retinal research, RCA operates a leading clinical research network with 50+ clinical trial sites spanning Phases I – IV studies.

At ASRS 2025, RCA’s physicians will lead sessions and presentations on clinical research, surgical techniques and novel therapeutic approaches, including:

• Subretinal delivery of an investigational gene therapy for wet AMD
• A therapeutic candidate targeting early Stargardt disease
• Innovative treatments — including novel drug combinations and a senolytic candidate — for diabetic macular edema

“ASRS’s annual meeting highlights the rapid pace of innovation in retina care, and the vital role practices play in advancing clinical studies to support the development of new therapies, including sight-saving treatments,” said Philip P. Storey, MD, MPH of Austin Retina Associates. “We’re focused on providing our patients with the highest quality of care. We continue to leverage RCA’s infrastructure and resources to expand our research program and provide patients access to the latest retina research and clinical trials.”

For more information about RCA Research, visit:
www.retinaconsultantsofamerica.com/rca-research

Diabetic Retinopathy

• Murtaza K. Adam, MD – Volumetric Analysis of Hard Exudates on OCT [July 31 | 10:51 – 10:54]
• Eric W. Schneider, MD, FASRS – Aflibercept 8 mg: PHOTON Study 156-Week Results [July 31 | 11:21 – 11:24]
• Jeremiah Brown, MD, MS, FASRS – Tie2 Agonist RO7446603 with Aflibercept/Faricimab [July 31 | 11:41 – 11:44]
• Dilsher S. Dhoot, MD – Suprachoroidal Avoralstat in Rabbit Model [July 31 | 11:47 – 11:50]
• Dante Pieramici, MD – Senolytic Candidate UBX1325: BEHOLD & ASPIRE Trials [July 31 | 11:53 – 11:56]

Dry AMD

• Edward Wood, MD, FASRS – Combined Anti-VEGF & Anticomplement Safety [July 31 | 2:41 – 2:44]
• David M. Brown, MD – CFH Supplementation Phase 2 Trial [August 2 | 11:52 – 11:55]

Wet AMD

• Charles C. Wykoff, MD, PhD, FASRS – COAST Phase 3: Sozinibercept + Aflibercept [August 1 | 11:21 – 11:24]
• John A. Wells, MD, FACS – PRISM Phase 2b: 4D-150 52-Week Results [August 1 | 11:24 – 11:27]
• Robert L. Avery, MD – Subretinal Gene Therapy ABBV-RGX-314 [August 1 | 1:46 – 1:49]

Macular Pucker – Epiretinal Membrane & Holes

• Vivek Chaturvedi, MD, FASRS – Hyperacute ERMs After Retinal Detachment Repair [July 31 | 4:55 – 4:58]

Surgical Techniques & Complications

• Kourous A. Rezaei, MD – Novel 27-Gauge Multispot Laser Probe Evaluation [August 1 | 8:03 – 8:06]
• Philip P. Storey, MD, MPH – Prefilled Syringe Impact on Endophthalmitis Rates [August 1 | 9:26 – 9:29]

Ocular Oncology

• Amy C. Schefler, MD, FACS, FASRS – BAP1 Mutations in Uveal Melanoma [August 1 | 2:50 – 2:53]
• David A. Reichstein, MD – Validation of 16-Protein Uveal Tumor Test [August 1 | 2:53 – 2:56]

Hereditary Retinal Disease & Genetics

• Kenneth C. Fan, MD, MBA – Gildeuretinol Slows Early Stargardt Progression [August 1 | 4:53 – 4:56]

Retinal Detachment

• Philip J. Ferrone, MD, FASRS – Intravitreal Methotrexate for Pediatric PVR [August 2 | 9:21 – 9:24]

Retinal Vascular Disease

• Hesham Gabr, MD – Surgical Outcomes for Sickle Cell Retinopathy [August 2 | 3:55 – 3:58]

Panels, Debates & Awards

• Retina Battle – Rezaei, Pearlman [July 30 | 11:30 – 12:30]
• Retinalaws – Rezaei, Emerson, Wykoff [July 30 | 12:30 – 1:30]
• Surgical Case Conference – Emerson [July 30 | 1:30 – 3:00]
• Case-Based Panel: Diabetic Retinopathy – Wykoff [July 31 | 12:15 – 12:36]
• Awards: Retina Hall of Fame – John T. Thompson, MD [August 1 | 12:29 – 12:31]
• Invited Talk: Managing Nevi for Vitreoretinal Surgeons – Schefler [August 1 | 2:37 – 2:47]